SCHEMBL25757029

SCHEMBL25757029

COc1ccc(NC(=O)c2ccccc2Cl)cc1S(=O)(=O)Nc1ccc(Br)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 8/20 0.67
MEN1 O00255 6/20 0.67
LMNA P02545 6/20 0.67
SMN1; SMN2 Q16637 6/20 0.67
ALDH1A1 P00352 4/20 0.67
GAA P10253 3/20 0.67
ALOX12 P18054 2/20 0.67
CRHBP P24387 1/20 0.67
CRHR2 Q13324 1/20 0.67
MAPT P10636 11/20 0.66
GPR27 Q9NS67 1/20 0.55
HTT P42858 2/20 0.55
POLB P06746 1/20 0.55
L3MBTL1 Q9Y468 1/20 0.55
KDM4E B2RXH2 3/20 0.54
NPC1 O15118 3/20 0.54
HPGD P15428 2/20 0.53
TNF P01375 1/20 0.52
NOD2 Q9HC29 1/20 0.52
NOD1 Q9Y239 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25755504 0.85 MAPT (0.82) KMT2AMEN1LMNASMN1; SMN2ALDH1A1
SCHEMBL25755514 0.84 KMT2A (0.64) KMT2AMEN1LMNASMN1; SMN2ALDH1A1
SCHEMBL25753999 0.81 KMT2A (0.79) KMT2AMEN1LMNASMN1; SMN2ALDH1A1
SCHEMBL27181407 0.80 MAPT (1.00) KMT2AMEN1LMNASMN1; SMN2ALDH1A1
SCHEMBL30926791 0.80 MAPT (1.00) KMT2AMEN1LMNASMN1; SMN2ALDH1A1
SCHEMBL27180374 0.80 MAPT (0.79) KMT2AMEN1LMNASMN1; SMN2ALDH1A1
SCHEMBL30926466 0.80 MAPT (0.79) KMT2AMEN1LMNASMN1; SMN2ALDH1A1
SCHEMBL25755590 0.79 KMT2A (0.67) KMT2AMEN1LMNASMN1; SMN2ALDH1A1
SCHEMBL17980878 0.79 KMT2A (0.61) KMT2AMEN1LMNASMN1; SMN2ALDH1A1
SCHEMBL30926976 0.79 MAPT (0.82) KMT2AMEN1LMNASMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230174523-A1 BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF AMATHUS THERAPEUTICS, INC. (US) 2023-06-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230174523-A1 BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF TRAP1, PINK1, TP53BP1 KMT2A 4864/4885MEN1 3902/4885LMNA 3435/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.